NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. 

NovaBay received its grant for its program to treat Impetigo. Impetigo is a highly contagious superficial bacterial infection of the skin that affects mostly children. Methicillin-resistant S. aureus (MRSA) is being observed with increasing frequency in this population.  Impetigo is currently being treated with antibiotic ointments, to which bacteria is developing resistance. 


 NovaBay Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New approach transforms oldest antibiotics into safer, stronger drugs